Engaging African Diaspora in the Fight against Vaccine Hesitancy

Bernadette Ateghang-Awankem¹ and Kenneth Yongabi Anchang^2,

¹Menda Health Systems, African Women 4 Empowerment, Nussloch, Germany

²Faculty of Health Science, College of Medicine, Imo State University, Owerri, Nigeria

Cite this paper:
Bernadette Ateghang-Awankem and Kenneth Yongabi Anchang. Engaging African Diaspora in the Fight against Vaccine Hesitancy. American Journal of Public Health Research. 2021; 9(1):28-37. doi: 10.12691/ajphr-9-1-4

Abstract

Vaccination acceptance is important for health security. In other to improve on the acceptance of any successful COVID19 vaccine, factors that might influence vaccine hesitancy have to be addressed. Vaccine hesitancy could describe someone who does not have a fully formed opinion about vaccination. They may refuse some vaccines and take others. They may delay the schedule, but eventually fully vaccinate their children. Vaccine hesitant individuals are the most likely to be swayed by anti-vaccine sentiments. These sentiments have the potential to significantly increase the severity of an outbreak. If enough hesitant individuals opt out of a new Covid-19 vaccine, this could undermine efforts to control the outbreak globally, and keep the disease in wide circulation. This article is intended to emphasize on the role of African diaspora as Influencers. The African diaspora, through remittance, influence economic and healthcare decision of the recipient families in their countries of origin. We hereby make a case for why it is important to analyze the perception of African Diasporas towards the COVID-19Vaccine and engage with them within a framework of health promotion and civic literacy, with the objective of generating demand for COVID-19 immunization, bearing in mind that there is no single strategy can address all of the different dimensions of hesitancy.

Keywords:
African Diaspora remittance vaccine hesitancy

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	IOM. (2004). Glossary on Migration. Geneva: https://www.iom.int/.
[2]	African Union. (2005). Meeting of Experts on the Definition of the African Diaspora 11 - 12 April 2005 Addis Ababa. Ethiopia: African Union.
[3]	Ionescu, D. (2006). Engaging Diasporas as Development Partners for Home and Destination Countries: Challenges for Policymakers. Geneva: International Organisation for Migration.
[4]	Dr Mohamoud, A. A. (2003). AFRICAN DIASPORA AND AFRICAN DEVELOPMENT Background paper for AfroNeth 5 December 2003.
[5]	Mohan, G., & Zack‐Williams, A. (2007, Feb 25). Globalisation from below: conceptualising the role of the African diasporas in africa's development. Review of African Political Economy, pp. P211-236.
[6]	Carling, J. (2003). Emigration, Return and Development in Cape Verde. International Workshop on Migration and Poverty in West Africa at the Sussex Centre for Migration Research. Sussex: University of Sussex
[7]	Larson, H., Jarrett , C., Eckersberger, E., Smith, D., & Paterson, P. (2014). Understanding vaccine hesitancy around vaccines and vaccination from a global perspective: A systematic review of published literature, 2007-2012. Vaccine, pp. 32(19): 2150-9.
[8]	CDC. (2016). Flu Vaccine Coverage, United States, 2015-16 Influenza. . Centers for Disease Control and Prevention.
[9]	Lu, P., Singleton , J., Euler , E., Williams , W., & Bridges , C. (2013). Seasonal Influenza Vaccination Coverage Among Adult Populations in the United States, 2005-2011. American Journal of Epidemiology, pp. 178(9):1478-1487.
[10]	Dong, E., Du , H., & Gardner, L. (2020). An interactive web-based dashboard to track COVID-19 in real time. . Lancet Infect Dis , pp. 20(5):533-4.
[11]	CDC. (2019). CDC. Flu vaccination coverage, United States, 2018-19 Influenza Season. 2019. https ://www.cdc.gov/flu/fluva xview /cover age-1819e stima tes.htm. Accessed 3 Apr 2020.
[12]	Bill & Melinda Gates Foundation. (2018). The Goalkeepers Report 2018. https ://www.gates found ation .org/goalk eeper s/report. Accessed 3 Apr 2020.
[13]	HSC. (2006). National strategy for pandemic influenza: implementation plan. Washington, DC: Government Printing Office; 2006. Homeland Security Council.
[14]	DHHS. (2019). Crimson Contagion 2019 Functional Exercise Draft After-Action Report.October 2019. US Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response.
[15]	Gates, B. (2020). Responding to Covid-19—a once-in-a-century pandemic? . NEJM, p. https://doi.org/10.1056/NEJMp 20037 62.
[16]	Dabbagh, A., Laws, R., & Steulet, C. (2018). Dumolard L, Mulders MN, Kretsinger K, Alexander JP, Rota PA, Goodson JL. Progress toward regional measles elimination—worldwide, 2000-2017. MMWR., pp. 67: 1323-9.
[17]	Yang , L., Grenfell, B., & Mina, M. (2019). Measles vaccine escape: Should we be concerned? . Eur J Epidemiology, pp. 34: 893-6.
[18]	WHO. (2019). Report of the SAGE Working Group on Immunization April 2019. . Geneva: World Health Organization.
[19]	Schuster, M., Eskola, & Duclos, P. (2015). SAGE Working Group. Review of Vaccine Hesitancy: Rationale, Remit, and Methods. Vaccine. , pp. 33(34):4157-4160.
[20]	MacDonald , N. (2015). Vaccine hesitancy: Definition, Scope and Determinants. . Vaccine, pp. 33(34): 4161-4164.
[21]	Dubé, E., Laberge, C., Guay, M., Bramadat, P., & Roy, R. (2013). Vaccine Hesitancy: An Overview. Human vaccines & immunotherapeutics., pp. 9(8):1763-73.
[22]	Larson , H., Schulz, W., Tucker , J., & Smith , D. (2015). Measuring Vaccine Confidence: Introducing a Global Vaccine Confidence Index. . PLoS currents. , p. 7.
[23]	Quinn, S., Jamison, A., Musa, D., Hilyard, K., & Freimuth, V. (2016, Dec 29). Exploring the Continuum of Vaccine Hesitancy Between African American and White Adults: Results of a Qualitative Study. PLOS Currents Outbreaks., p. Edition 1.
[24]	U.S. Census Bureau. (2019). Age and sex composition in the United States: 2019. . https://www.census.gov/data/tables/2019/demo/age-and-sex/2019- age-sex-composition.html(accessed: 23rd June 2020).
[25]	Larson , H., Clarke, R., Jarrett, C., Eckersberger, E., Levine, Z., Schulz, W., & Paterson, P. (2018). Measuring trust in vaccination; A systematic review. Human Vaccines & Immunotherapeutics, pp. 1-11.
[26]	Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., & Song, J. (2020, FEB 20). A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med.
[27]	Wu, F., Zhao, S., Yu, B., Chen, Y., Wang, W., Song, Z., . . . Zhang, Y. (2020). A new coronavirus associated with human respiratory disease in China . Nature, pp. 579(7798), 265-269.
[28]	Zimmermann, P., & Curtis, N. (2020). Coronavirus infections in children including COVID-19: an overview of the epidemiology, clinical features, diagnosis, treatment and prevention options in children. Pediatr Infect Dis J, pp. 39(5):355-68.
[29]	Boopathi, S., Poma, A., & Kolandaivel, P. (2020, April 30). Novel coronavirus structure, mechanism of action, antiviral drug promises and rule out against its treatment. J Biomol Struct Dyn, pp. 1-10.
[30]	Buchholz, U., Bukreyev, A., Lijuan, Y., Lamirande, E., Murphy, B., Subbarao, K., & Collins, P. (2004). Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. Proc Natl Acad Sci U S A, pp. 101(26): 9804-9.
[31]	Walls, A., Wall, A., Park, Y.-J., David, McGuire, A., & Veesler, D. (2020). Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell.
[32]	Roper , R., & Rehm, K. (2009). SARS vaccines: where are we? Expert Rev Vaccines, pp. 8(7):887-98.
[33]	Edridge, A., Kaczorowska, J., Hoste , A., Bakker, M., & Klein, M. (2020.). Seasonal coronavirus protective immunity is short-lasting. Nature Medicine.
[34]	Lurie, N., Saville, M., Hatchett, R., & Halton, J. (2020). Developing covid-19 vaccines at pandemic speed. N Engl J Med, pp. 382(21): 1969-73.
[35]	WHO. (2016). Ebola Response Team. After Ebola in West Africa — unpredictable risks, preventable epidemics. N Engl J Med, pp. 375(6):587-96.
[36]	Huber, C., Finelli, L., & Stevens, W. (2018). The economic and social burden of the 2014 Ebola outbreak in West Africa. J Infect Dis, pp. 218(Supplement_5). p. S698-S704.
[37]	Habibzadeh, P., & Stoneman, E. (2020). The novel Coronavirus: a bird’s eye view. Int J Occup Environ Med., pp. 11(2): 65-71.
[38]	Ahmed, S., Quadeer, A., & McKay, M. (2020). Preliminary identification of potential vaccine targets for 2019-nCoV based on SARS-CoV immunological studies. bioRxiv.
[39]	Shang, W., Yang, Y., Rao, Y., & Rao, X. (2020). The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines. Vaccines, p. 5(1): 18.
[40]	Casadevall, A., & Pirofski, L. (2020). The convalescent sera option for containing COVID-19. The Journal of clinical investigation, pp. 130(4), 1545-1548
[41]	Moderna Therapeutics. (2020). First coronavirus vaccine trial in the US is recruiting volunteers. https://www.lives cienc e.com/us- coron aviru s-vacci ne-trial -recru iting .html
[42]	WHO. (2020). DRAFT landscape of COVID-19 candidate vaccines-20 April 2020. Geneva:: World Health Organization.
[43]	Kim, Y., Dema, B., & Reyes-Sandoval, A. (2020). COVID-19 vaccines: breaking record times to first-in-human trials. Vaccines, p. 5(1): 34.
[44]	He, Y., Zhou, Y., Liu, S., Kou, Z., Li, W., Farzan, M., & Jiang, S. (2004). Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine. . Biochem Biophys Res Commun, pp. 324(2): 773-81.
[45]	Wang, Q., Wong, G., Lu, G., Yan, J., & Gao, G. (2016). MERS-CoV spike protein: targets for vaccines and therapeutics. Antiviral Research, pp. 133:165-77.
[46]	Sanofi. (2020). Sanofi Reports Faster Progress for COVID-19 Vaccine Candidate. https :// www.fdane ws.com/artic les/19776 5: FDANews.
[47]	Chan, J.-W., Yuan, S., Kok , K.-H., To , K.-W., Chu, H., Yang, J., . . . Liu, J. (2020). A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet, pp. 514-523.
[48]	Makoni, M. (04. September 2020). COVID-19 vaccine trials in Africa. The Lancet Respiratory Medicine.
[49]	Rowland, C., Johnson, C., & Wan, W. (2020). Even finding a COVID-19 vaccine won’t be enough to end the pandemic. Washington Post, https://www.washingtonpost.com/business/2020/05/11/coronaviru s-vaccine-global-supply/.
[50]	Sanche, S., Lin, Y., Xu, C., Romero-Severson, E., Hengartner, N., & Ke, R. (2020). Sanche S, Lin YT, Xu C, Romero-Severson E, Hengartner N, Ke R. High contagiousness and rapid spread of severe acute respiratory syndrome coronavirus 2. Emerg Infect Dis., p. 26(7).
[51]	Trujillo, K., & Motta, M. (2020). A majority of vaccine skeptics plan to refuse a COVID-19 vaccine, a study suggests, and that could be a big problem. Published May 4, 2020. Accessed May 6, 2020. https://theconversation.com/a-majority-of-vaccineskeptics- plan-to-refuse-a-covid-19-vaccine-astudy-suggests-and-that- could-be-a-big-problem-137559.
[52]	Edwards, K., & Hackell, J. (2016). Committee on Infectious Diseases, the Committee on Practice and Ambulatory Medicine. Countering vaccine hesitancy. Pediatrics, pp. 138(3):2016-2146.
[53]	Bode, L., & Vraga , E. (2018). See something, say something: correction of global health misinformation on social media. . Health Commun., pp. 33(9):1131-1140.
[54]	Kempe , A., O'Leary, S., Kennedy, A., Crane, L., Allison, M., Beaty, B., . . . Jimenez-Zambrano, A. (2015). Physician response to parental requests to spread out the recommended vaccine schedule. . Pediatrics. , pp. 135(4):666-677.
[55]	Schoch-Spana, M., Brunson, E., Long, R., Ravi, S., Ruth, A., & Trotochaud, M. (2020). The Public’s Role in COVID-19 Vaccination: Planning Recommendations Informed by Design Thinking and the Social, Behavioral, and Communication Sciences. Baltimore, MD: Johns Hopkins Center for Health Security.
[56]	Mekonnen, M. (2017). Transnational Migration Development Nexus. LIT Verlag.
[57]	IOM. (2012). Developing a Road Map for Engaging Diasporas in Development. Geneva: International Organization for Migration (IOM)
[58]	Agunias, D. R., & Newland, K. (2012). Developing a Road Map for Engaging Diasporas in Development A HANDBOOK FOR POLICYMAKERS AND PRACTITIONERS IN HOME AND HOST COUNTRIES. Geneva: International Organization for Migration; Migration Policy Institute.